{"id":10301,"date":"2025-08-18T19:20:58","date_gmt":"2025-08-18T19:20:58","guid":{"rendered":"https:\/\/organonpro.com\/en-us\/product\/bilprevda-2\/why-bilprevda\/"},"modified":"2026-02-18T15:16:40","modified_gmt":"2026-02-18T15:16:40","slug":"why-bilprevda","status":"publish","type":"product","link":"https:\/\/organonpro.com\/en-us\/product\/bilprevda\/why-bilprevda\/","title":{"rendered":"Why BILPREVDA"},"content":{"rendered":"\n

When their bones are at risk, BILPREVDA has your back<\/h1>\n\n\n\n

Though covered by Medicare, the cost of XGEVA (denosumab) may represent a barrier to care or influence treatment decisions.10-12 <\/sup>As of 2025, BILPREVDA is ~51% less expensive than XGEVA.<\/strong>* Referenced prices are derived from published price lists and do not necessarily reflect actual prices paid by consumers or dispensers. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs.<\/p>\n\n\n\n


*Based on comparison of wholesale acquisition cost (WAC) per dose. WAC prices: BILPREVDA $1,688.00 per dose; XGEVA $3,449.74 per dose. (Source: Medi-Span\u00ae <\/sup>Price Rx\u00ae <\/sup>as of Sept 2025).<\/p>\n\n\n\n

<\/div>\n\n\n\n

BILPREVDA is as safe and effective as the reference product, XGEVA5<\/sup><\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
See a clinical summary<\/a><\/div>\n<\/div>\n\n\n
\n
\"Woman<\/figure><\/div>\n\n\n

Computer-generated X-ray depiction of spine represents one of the common sites of bone metastases.1<\/sup><\/p>\n\n\n\n

BILPREVDA is an approved biosimilar to XGEVA<\/h2>\n\n\n\n
<\/div>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

PD, pharmacodynamics; PK, pharmacokinetics.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Pharmacokinetic similarity study14<\/sup>:<\/h3>\n\n\n\n

A 2-part pharmacokinetic similarity study of BILPREVDA (HLX14) and reference denosumab demonstrated biosimilarity in PK, PD, safety, and immunogenicity endpoints.<\/p>\n\n\n\n

Comparative clinical study<\/strong>13<\/sup>:<\/strong><\/h3>\n\n\n\n

A randomized, double-blind, parallel-controlled, multicenter comparative clinical study in postmenopausal women with osteoporosis at high risk for fracture compared BILPREVDA (HLX14) to reference denosumab and evaluated efficacy, PD, PK, safety, and immunogenicity.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Support your patients through access<\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n
Explore patient access<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
See our experience<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

BILPREVDA is FDA approved for use in the same 3 indications as XGEVA, including for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors<\/h2>\n\n\n
\n
\n
\n
\n
\n
\n

\n